The LZTS1 (Leucine Zipper Tumor Suppressor 1) antibody targets a protein encoded by the *LZTS1* gene, also known as FEZ1 or PLECKSTRIN-2. Initially identified as a tumor suppressor, LZTS1 is located on chromosome 8p22. a region frequently deleted in cancers such as prostate, breast, and bladder malignancies. The LZTS1 protein contains a leucine zipper domain, suggesting roles in protein-protein interactions, and is implicated in regulating cell cycle progression, differentiation, and apoptosis. Dysregulation of LZTS1. often through promoter hypermethylation or loss of heterozygosity, is linked to cancer progression, where its downregulation correlates with uncontrolled proliferation, metastasis, and poor prognosis. Studies suggest LZTS1 modulates key pathways like Wnt/β-catenin and epithelial-mesenchymal transition (EMT). Antibodies against LZTS1 are vital tools for detecting its expression and localization in tissues or cell lines, aiding in assessing its diagnostic or prognostic relevance in cancer. They also enable functional studies, such as overexpression or knockdown experiments, to explore mechanisms underlying tumor suppression. Recent research highlights its potential role beyond oncology, including neurodevelopment and infection responses, broadening the scope of LZTS1 antibody applications in biomedical research and therapeutic target discovery.